Mensinorm Set (Follicle-Stimulating Hormone, Luteinising Hormone)

FSH binds to receptors on ovarian granulosa cells, stimulating follicle recruitment, growth, and estradiol production. LH binds to receptors on theca cells and mature follicles, promoting androgen synthesis and final maturation, which together enable ovulation when the hormonal environment is appropriate.

The dose of Mensinorm Set is individualized. A qualified prescriber determines the amount, frequency, and duration of treatment based on the patient’s ovarian response, hormone levels, and the specific clinical protocol being followed.

Mensinorm Set is not intended for use during an established pregnancy, and its safety in breastfeeding women has not been established. It should only be used under medical supervision in the pre‑conception or early treatment phases as directed by a fertility specialist.

To order Mensinorm Set, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and any required import documentation.

Mensinorm Set combines both FSH and LH in a single injectable formulation, which can simplify dosing compared with regimens that require separate FSH and LH preparations. Clinical efficacy is comparable to other recombinant or purified gonadotropin products, while the choice often depends on physician preference, patient response, and cost considerations.

Mensinorm Set must be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. Before use, allow the product to reach room temperature if required, and inspect for particulate matter or discoloration.

Mensinorm Set is administered by subcutaneous injection, typically into the abdominal wall or thigh. The injection is performed by a trained healthcare professional or a patient who has been instructed in aseptic technique and proper dosing, following the prescriber’s specific regimen.

The most serious risks include severe ovarian hyperstimulation syndrome (OHSS), which can cause abdominal pain, rapid weight gain, and fluid accumulation, as well as the possibility of multiple pregnancy, allergic reactions such as anaphylaxis, and rare thromboembolic events. Prompt medical attention is required if any of these occur.

Mensinorm Set should not be used in individuals with known hypersensitivity to any component of the product, in patients with uncontrolled thyroid or adrenal disorders, in those with active ovarian cysts that could increase OHSS risk, or in women who are already pregnant. Contra‑indications are determined by the treating physician.